Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Martins, Karen A O ^a   Steffens, Jesse T ^a   Van Tongeren, Sean A ^a   Wells, Jay B ^a   Bergeron, Alison A ^a   Dickson, Samuel P ^a   Dye, John M ^a   Salazar, Andres M ^b   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Oncovir Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CELL PROTEIN; CYTOKINE; DOUBLE STRANDED RNA; HILTONOL; INTERLEUKIN 6; KC PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE; CARBOXYMETHYLCELLULOSE; IMMUNOLOGICAL ADJUVANT; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FEMALE; GUINEA PIG; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; LYMPH NODE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MOLECULAR DYNAMICS; MOUSE; NATURAL KILLER CELL; NONHUMAN; UPREGULATION; VIRUS IDENTIFICATION; VIRUS LIKE AGENT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CARBOXYMETHYLCELLULOSE SODIUM; CYTOKINES; EBOLAVIRUS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; MICE, INBRED C57BL; POLY I-C; POLYLYSINE; TOLL-LIKE RECEPTORS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84896082313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089735     Document Type: Article

References (59)

1. Falzarano D, Geisbert TW, Feldmann H (2011) Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines 10: 63-77.
2. Fausther-Bovendo H, Mulangu S, Sullivan NJ (2012) Ebolavirus vaccines for humans and apes. Curr Opin Virol 2: 324-329.
3. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV (2011) Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 23: 377-382.
4. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, et al. (2004) Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 200: 169-179. (Pubitemid 38982176)
5. Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, et al. (2005) Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 175: 1184-1191. (Pubitemid 41095006)
6. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, et al. (2004) Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 22: 3495-3502. (Pubitemid 39078769)
7. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, et al. (2005) Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23: 3033-3042. (Pubitemid 40462443)
8. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, et al. (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196 Suppl 2: S430-437. (Pubitemid 351417291)
9. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, et al. (2008) Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 15: 460-467. (Pubitemid 351967082)
10. Swenson DL, Warfield KL, Kuehl K, Larsen T, Hevey MC, et al. (2004) Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol 40: 27-31. (Pubitemid 38083355)
11. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, et al. (2003) Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 100: 15889-15894. (Pubitemid 38021085)
12. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, et al. (2002) Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 195: 593-602. (Pubitemid 34461504)
13. Licata JM, Johnson RF, Han Z, Harty RN (2004) Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol 78: 7344-7351. (Pubitemid 38915880)
14. Wahl-Jensen V, Kurz SK, Hazelton PR, Schnittler HJ, Stroher U, et al. (2005) Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 79: 2413-2419. (Pubitemid 40204596)
15. Brunner R, Jensen-Jarolim E, Pali-Scholl I (2010) The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett 128: 29-35.
16. Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12: 509-517.
17. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
18. Steinhagen F, Kinjo T, Bode C, Klinman DM (2011) TLR-based immune adjuvants. Vaccine 29: 3341-3355.
19. Wang Y, Cella M, Gilfillan S, Colonna M (2010) Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J Immunol 184: 2751-2755.
20. Hausmann S, Marq JB, Tapparel C, Kolakofsky D, Garcin D (2008) RIG-I and dsRNA-induced IFNbeta activation. PLoS One 3: e3965.
21. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, et al. (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-1602.
22. Nordlund JJ, Wolff SM, Levy HB (1970) Inhibition of biologic activity of poly I: poly C by human plasma. Proc Soc Exp Biol Med 133: 439-444.
23. Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, et al. (1975) A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 132: 434-439.
24. Houston WE, Crabbs CL, Stephen EL, Levy HB (1976) Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect Immun 14: 318-319.
25. Sammons ML, Stephen EL, Levy HB, Baron S, Hilmas DE (1977) Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. Antimicrob Agents Chemother 11: 80-83. (Pubitemid 8022376)
26. Stevenson HC, Abrams PG, Schoenberger CS, Smalley RB, Herberman RB, et al. (1985) A phase I evaluation of poly(I,C)-LC in cancer patients. J Biol Response Mod 4: 650-655. (Pubitemid 16209274)
27. Lampkin BC, Levine AS, Levy H, Krivit W, Hammond D (1985) Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. Cancer Res 45: 5904-5909. (Pubitemid 16218608)
28. Lampkin BC, Levine AS, Levy H, Krivit W, Hammond D (1985) Phase II trial of poly(I,C)-LC, an interferon inducer, in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. J Biol Response Mod 4: 531-537. (Pubitemid 16241553)
29. Puri SK, Dutta GP, Levy HB, Maheshwari RK (1996) Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys. J Interferon Cytokine Res 16: 49-52. (Pubitemid 26020587)
30. Champney KJ, Levine DP, Levy HB, Lerner AM (1979) Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. Infect Immun 25: 831-837. (Pubitemid 9251883)
31. Krown SE, Kerr D, Stewart WE, 2nd, Field AK, Oettgen HF (1985) Phase I trials of poly(I,C) complexes in advanced cancer. J Biol Response Mod 4: 640-649. (Pubitemid 16209273)
32. Levine AS, Levy HB (1978) Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep 62: 1907-1912. (Pubitemid 9120849)
33. Kastenmuller K, Espinosa DA, Trager L, Stoyanov C, Salazar AM, et al. (2012) Full-length P. Falciparum Circumsporozoite Protein Administered with Poly-ICLC or GLA/SE Elicits Potent Antibody and CD4+ T Cell Immunity and Protection in Mice. Infect Immun.
34. Park H, Adamson L, Ha T, Mullen K, Hagen SI, et al. (2013) Polyinosinic-Polycytidylic Acid Is the Most Effective TLR Adjuvant for SIV Gag Protein-Induced T Cell Responses In Nonhuman Primates. J Immunol 190: 4103-4115.
35. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, et al. (2009) Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5: e1000373.
36. Cho HI, Celis E (2009) Optimized peptide vaccines eliciting extensive CD8 Tcell responses with therapeutic antitumor effects. Cancer Res 69: 9012-9019.
37. Flynn BJ, Kastenmuller K, Wille-Reece U, Tomaras GD, Alam M, et al. (2011) Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 108: 7131-7136.
38. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178: 651-661. (Pubitemid 28397211)
39. Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, et al. (2005) Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 79: 14189-14196. (Pubitemid 41552717)
40. Shedlock DJ, Aviles J, Talbott KT, Wong G, Wu SJ, et al. (2013) Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 21: 1432-1444.
41. Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, et al. (2013) Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 9: e1003389.
42. Wong G, Richardson JS, Pillet S, Patel A, Qiu X, et al. (2012) Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 4: 158ra146.
43. Thakur A, Pedersen LE, Jungersen G (2012) Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 30: 4907-4920.
44. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850. (Pubitemid 47038186)
45. Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, et al. (2013) Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 110: 1893-1898.
46. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, et al. (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 109: 5034-5039.
47. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, et al. (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4: 1009-1015. (Pubitemid 37265922)
48. Shortman K, Heath WR (2010) The CD8+ dendritic cell subset. Immunol Rev 234: 18-31.
49. den Haan JM, Lehar SM, Bevan MJ (2000) CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192: 1685-1696.
50. Joffre OP, Segura E, Savina A, Amigorena S (2012) Cross-presentation by dendritic cells. Nat Rev Immunol 12: 557-569.
51. Antonelli LR, Gigliotti Rothfuchs A, Goncalves R, Roffe E, Cheever AW, et al. (2010) Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 120: 1674-1682.
52. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, et al. (2011) Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 208: 2357-2366.
53. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, et al. (2010) Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 28: 7256-7266.
54. Li Y, Hu Y, Jin Y, Zhang G, Wong J, et al. (2011) Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection. J Gene Med 13: 60-72.
55. Martins KA, Warren TK, Bavari S (2013) Characterization of a putative filovirus vaccine: Virus-like particles. Virol Sin 28: 65-70.
56. Tarrant JM (2010) Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci 117: 4-16.
57. Salazar AM, Levy HB, Ondra S, Kende M, Scherokman B, et al. (1996) Longterm treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38: 1096-1103; discussion 1103-1094.
58. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, et al. (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29: 330-336.
59. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, et al. (2010) A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol 12: 1071-1077.